Keyphrases
Age at Presentation
16%
Ataxia
16%
Biopsy-proven
16%
Bone Pain
16%
BRAF mutation
16%
Central Nervous System
16%
Cerebral Blood Flow
16%
Cladribine
16%
Clinical Analysis
16%
Clinical Characteristics
16%
Clinical Considerations
100%
Clinical Events
16%
Complex Patients
16%
Complication Management
16%
Diagnosis Management
16%
Diagnosis Treatment
16%
Dysarthria
16%
Dyspnea
16%
Erdheim-Chester Disease
100%
ERK Pathway
16%
Exophthalmos
16%
Fever
16%
Follow-up Time
16%
Great Vessels
16%
Illness
16%
Infliximab
16%
Interferon Treatment
16%
Langerhans Cell Histiocytosis
16%
Lung
16%
Medical Challenges
16%
Multidisciplinary Team
16%
Multisystemic
33%
Neurological Improvement
16%
Pathological Characteristics
16%
Patient Management
100%
Pericardial Effusion
16%
Perivenous
16%
Pituitary Gland
16%
Pleura
16%
Polydipsia
16%
Polyuria
16%
Radiological Characteristics
16%
Renovascular Hypertension
16%
Retina
16%
Retroperitoneum
16%
Therapeutic Approaches
16%
Treatment Management
16%
V600E-BRAF
16%
Vemurafenib
16%
Volume Reduction
16%
Biochemistry, Genetics and Molecular Biology
Brain Blood Flow
100%
Cladribine
100%
Infliximab
100%
interferon
100%
Interferon
100%
Langerhans Cell
100%
Pericardial Effusion
100%
Vemurafenib
100%
Medicine and Dentistry
Ataxia
16%
Biopsy
16%
Bone Pain
16%
Brain Blood Flow
16%
Central Nervous System
16%
Cladribine
16%
Disease
16%
Dysarthria
16%
Dyspnea
16%
Erdheim-Chester Disease
100%
Exophthalmos
16%
Histiocytosis
16%
Infliximab
16%
Interferon
16%
Orphan
16%
Pericardial Fluid
16%
Physical Disease by Body Function
16%
Pituitary Gland
16%
Polydipsia
16%
Polyuria
16%
Renovascular Hypertension
16%
Retroperitoneum
16%
Skeleton
16%
Vemurafenib
16%
Visceral Pleura
16%
Pharmacology, Toxicology and Pharmaceutical Science
Ataxia
16%
Bone Pain
16%
Cladribine
16%
Disease
16%
Dysarthria
16%
Dyspnea
16%
Erdheim Chester Disease
100%
Exophthalmos
16%
Histiocytosis
16%
Infliximab
16%
Interferon
16%
Pericardial Effusion
16%
Physical Disease by Body Function
16%
Polydipsia
16%
Polyuria
16%
Renovascular Hypertension
16%
Vemurafenib
16%